Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study on patient outcomes after metal-on-metal hip replacement revision surgery has been selected as part of a prestigious 'Game Changers' session at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting.

The biggest study in the world of its kind, researchers specifically investigated outcomes after revision surgery performed for abnormal reactions to metal. The Program Committee for the conference, this year taking place in San Diego, selects work which they feel will change clinical practice within the next two to three years.

Approximately 1.5 million patients worldwide have metal-on-metal hip replacements for painful arthritis. Abnormal reactions to metal can develop which may cause surrounding tissue damage. Many patients with these reactions require further operations, known as revision surgery. Little is currently known about outcomes for patients following these further operations, though initial observations showed patients experienced poor results. This is concerning as most patients who received this type of hip replacement are young and active. Therefore poor results would have a significant impact on a patient's quality of life.

Read more (NDORMS website)

Similar stories

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.

Increased infectiousness of coronavirus variants explained

Researchers from the Universities of Oxford and Dundee have made a discovery that helps explain why variations in the virus causes COVID-19 to spread so rapidly.

RECOVERY Trial paper wins BMJ’s 2021 UK Research Paper of the Year Award

For the second year in a row, The British Medical Journal have selected a publication co-authored by Oxford University researchers for their prestigious UK Research Paper of the Year Award. This award recognises original UK research that has the potential to contribute significantly to improving health and healthcare.

Researchers awarded Wellcome Innovator Grant to investigate role of brainstem nucleus in human consciousness

Researchers at Oxford University have received a prestigious Wellcome Innovator Grant for investigating the role of the pedunculopontine nucleus (PPN) – a brainstem nucleus – in human consciousness.